Acadia Pharmaceuticals announces District Court ruling in its favor

Acadia Pharmaceuticals announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for Nuplazid, Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In this order, the court ruled in favor of Acadia on all of the disputed claim construction points. In the order, the court adopted Acadia’s interpretation of key disputed terms of the patent. Acadia believes that the court’s interpretations affirm the strength of the patent. As a result of this order, a claims construction hearing, which had been scheduled for December 19, has been cancelled by the court. The case remains scheduled for trial in December 2024. This was the second ruling issued by the court pertaining to Acadia’s patents covering Nuplazid. Earlier, in a separate litigation, the court granted summary judgment to Acadia, confirming validity of Acadia’s ‘740 composition of matter patent.